Address BSI and SSI risk factors as a part of the patient bathing process with

Chlorhexidine Gluconate 2% w/v Impregnated Pads

The threat of healthcare-acquired infections

Interventions designed to reduce healthcare-acquired infections (HAIs) are vital to reduce risk of morbidity and mortality.

The European Centre for Disease Prevention and Control (ECDC) estimates that on any given day, about 80,000 patients, i.e. one in 18 patients, in European hospitals have at least one healthcare-associated infection.1

Trust the licensed product

Chlorhexidine Gluconate 2% w/v Impregnated Pads are a licensed, medicinal product indicated for skin antisepsis as part of an advance preoperative cleansing regimen and general skin antisepsis. Be sure you’re getting the most from your product with approved claims that deliver real infection prevention outcomes.

  • Granted marketing authorisation July 2010
  • Proven to reduce a wide range of organisms including MRSA, VRE, Acinetobacter baumannii, Pseudomonas aeruginosa and various Streptococcus species on your patients’ skin.
REFERENCES: 1. European Centre for Disease Prevention and Control, Press Release: Each day, one in 18 patients in European hospitals has a healthcare-associated infection: ECDC estimates, Stockholm, 4 July, 2013.

Skin Antisepsis

DOWNLOAD BROCHURE DOWNLOAD ORDERING CATALOGUE

Marketing Authorisation Holder:
Sage Products Coöperatief U.A., Herikerbergweg 238, Luna ArenA, 1101 CM, Amsterdam, Netherlands.

Name of Product:
Chlorhexidine Gluconate 2% w/v Impregnated Pad.

Dosage Form: Impregnated Pad

Cost: £299 per case of 40 packages.

Indications:
Skin Antisepsis as part of an advanced preoperative cleansing regimen and general skin antisepsis. PL 43018/0001.

Warnings and Contra-Indications:
For external use only. Keep out of reach and sight of children. Do not use on premature or low birth weight infants or infants less than 2 months of age or receiving phototherapy. Do not use on patients with known allergies to chlorhexidine gluconate or any other ingredients in the product. Do not use immediately prior to any invasive techniques, such as venepuncture, lumbar puncture or surgery. Do not use on open skin wounds or broken skin. When using this product, keep out of eyes, ears, and mouth. May cause serious or permanent injury if chlorhexidine is permitted to enter and remain. If contact occurs, rinse with water right away. Do not use if irritation, sensitization, or allergic reaction occurs. Do not store above 25oC. Do not refrigerate or freeze. Store flat. Dispose of as solid waste. Do not flush pads in toilet. For posology, method of administration and side effects refer to SPC.

Supply Classifications: GSL

Date: September 2015

DOWNLOAD ORDERING CATALOGUE

9612-X_UK_CHG_6pk_NewLabelChlorhexidine Gluconate 2% w/v Impregnated Pad

6 cloths per package
Cloth size: 19cm x 19cm
40 packages/case
Reorder #9612-X

What the Experts Say

Chlorhexidine Gluconate (CHG) (PDF)
Excerpts from various published studies and articles

Clinical Support

Prevention of Colonization and Infection by Klebsiella pneumoniae Carbapenemase–Producing Enterobacteriaceae in Long-term
Acute-Care Hospitals (PDF)

Mary K. Hayden, Michael Y. Lin, Karen Lolans, Shayna Weiner, Donald Blom, Nicholas M. Moore, Louis Fogg, David Henry, Rosie Lyles, Caroline Thurlow, Monica Sikka, David Hines, and Robert A. Weinstein

Is Your Antiseptic Effective Against Clinical Multidrug-resistant Microorganisms? A Chlorhexidine Digluconate Formulation Demonstrating Efficacy Even at Lower Concentrations (PDF)
Nico T. Mutters, Frank Günther, Stefan Kaiser, Tamara Fries, Uwe Frank
Heidelberg University Hospital, Department of Infectious Diseases, Heidelberg, Germany

Chlorhexidine daily bathing: Impact on health care associated infections caused by gram-negative bacteria (PDF)
Nadim Cassir MD, Guillemette Thomas MD, Sami Hraiech MD,
Julie Brunet, Pierre-Edouard Fournier MD, PhD, Bernard La Scola MD, PhD,
Laurent Papazian MD, PhD

Daily Bathing with 2% CHG Washcloths Leads to Almost Total Elimination of MRSA Bacteraemia (PDF)
Wyncoll D, Shankar-Hari M, Beale R

Click for a complete listing of clinical evidence to support your prevention efforts.

Clinical Information

Evaluation Forms

Product Evaluation

Resources

Summary of Product Characteristics

MSDS/SDS Sheets

View all